Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia	Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute monocytic leukemia, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm	Recruiting	Phase 2	2026-08-13		NCT03737955

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Pfizer	431
University of Washington	397

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Fred Hutchinson Cancer Center/University of Washington Cancer Consortium	Seattle	United States	1

Clinical trials